0P
0P8.F Penumbra Inc
- Market cap
- EUR 11.4B
- P/E
- 85.5x
- P/B
- 8.03x
- ROE
- 9.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 0P8.F undervalued?
Graham numberThe Graham number of Penumbra Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Penumbra Inc fundamental analysis
No fundamental analysis for Penumbra Inc yet.
Penumbra Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide cathete…
Full company profilePenumbra Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Penumbra Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 263M | 334M | 445M | 547M | 560M | 748M | 847M | 1.06B | 1.19B | 1.40B | 1.57B |
| Gross Profit | 171M | 217M | 293M | 372M | 338M | 475M | 535M | 683M | 755M | 942M | 1.06B |
| Operating Income | -1.35M | 1.17M | 30.0M | 47.5M | -38.9M | -7.50M | 6.08M | 91.8M | 86.2M | 189M | 173M |
| EBITDA | - | 4.95M | 36.2M | 55.6M | -26.1M | 8.91M | 30.0M | 109M | 46.0M | 224M | 214M |
| Net Income | 14.8M | 4.66M | 6.60M | 48.5M | -15.7M | 5.28M | -2.00M | 91.0M | 14.0M | 178M | 146M |
| EPS | - | 0.14 | 0.19 | 1.38 | -0.43 | 0.14 | -0.05 | 2.35 | 0.36 | 4.53 | 3.71 |
| Balance Sheet | |||||||||||
| Total Assets | 308M | 477M | 515M | 666M | 823M | 1.24B | 1.37B | 1.56B | 1.53B | 1.83B | 2.03B |
| Total Liabilities | 41.7M | 76.3M | 92.6M | 180M | 185M | 290M | 372M | 377M | 382M | 399M | 442M |
| Shareholders' Equity | 267M | 400M | 422M | 486M | 641M | 954M | 999M | 1.18B | 1.15B | 1.43B | 1.58B |
| Cash & Short-term Investments | 13.2M | 50.6M | 67.9M | 72.8M | 69.7M | 59.4M | 69.9M | 167M | 324M | 187M | 254M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.8M | 12.7M | 28.8M | 26.7M | -33.2M | 9.50M | -55.7M | 62.4M | 168M | 239M | 233M |
| Capital Expenditure | 13.6M | 12.5M | 9.60M | 22.1M | 24.8M | 21.2M | 19.3M | 15.1M | 21.2M | 63.7M | 56.4M |
| Free Cash Flow | - | -2.34M | 19.2M | 4.54M | -58.0M | -11.7M | -75.0M | 47.3M | 147M | 175M | 176M |
| Ratios | |||||||||||
| ROE | 5.6% | 1.2% | 1.6% | 10.0% | -2.4% | 0.6% | -0.2% | 7.7% | 1.2% | 12.4% | 9.2% |
| ROA | 4.8% | 1.0% | 1.3% | 7.3% | -1.9% | 0.4% | -0.1% | 5.8% | 0.9% | 9.7% | 7.2% |
| Net Profit Margin | 5.6% | 1.4% | 1.5% | 8.9% | -2.8% | 0.7% | -0.2% | 8.6% | 1.2% | 12.7% | 9.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Penumbra Inc dividends
Penumbra Inc has not paid dividends in the last 9 fiscal years.
Who owns Penumbra Inc
- Insiders 2.95%
- Institutions 89.82%
- Public & others 7.24%
- Shares outstanding 39.4M
- Free float 38.3M
Penumbra Inc company profile
- Company name
- Penumbra Inc
- Ticker
- 0P8.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 4,700
- Fiscal year end
- December
- Address
- One Penumbra Place, Alameda, CA, United States, 94502
- Phone
- 510 748 3200
- Website
- penumbrainc.com
About Penumbra Inc
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Penumbra Inc management
10- Mr. Adam Elsesser J.D.Co-Founder, Chairman & CEO · born 1962
- Ms. Shruthi NarayanPresident · born 1985
- Dr. Arani Bose M.D.Co-Founder & Director · born 1962
- Ms. Maggie S. YuenChief Financial Officer · born 1972
- Mr. Lambert ShiuChief Accounting Officer · born 1980
- Ms. Johanna Roberts J.D.Executive VP, General Counsel & Secretary · born 1972
- Mr. Ben SorciExecutive Vice President of Operations
- Ms. Jee Hamlyn-HarrisInvestor Relations Officer
- Mr. Ben TompkinsExecutive Vice President of Development & Compliance
- Mr. Jason Richard MillsExecutive Vice President of Strategy